Chemed (CHE) Competitors

Medpace (NASDAQ:MEDP) and Chemed (NYSE:CHE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Does the media prefer MEDP or CHE?

In the previous week, Medpace had 10 more articles in the media than Chemed. MarketBeat recorded 21 mentions for Medpace and 11 mentions for Chemed. Chemed's average media sentiment score of 1.71 beat Medpace's score of 1.38 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	17 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has stronger earnings and valuation, MEDP or CHE?

Medpace has higher earnings, but lower revenue than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.11B	6.25	$404.39M	$13.45	34.89
Chemed	$2.51B	2.59	$302M	$19.45	22.98

Is MEDP or CHE more profitable?

Medpace has a net margin of 18.74% compared to Chemed's net margin of 11.56%. Medpace's return on equity of 67.66% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	18.74%	67.66%	21.86%
Chemed	11.56%	25.83%	17.77%

Which has more volatility and risk, MEDP or CHE?

Medpace has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Do institutionals & insiders believe in MEDP or CHE?

78.0% of Medpace shares are held by institutional investors. Comparatively, 95.8% of Chemed shares are held by institutional investors. 20.3% of Medpace shares are held by company insiders. Comparatively, 3.3% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts rate MEDP or CHE?

Medpace currently has a consensus target price of $406.60, suggesting a potential downside of 13.36%. Chemed has a consensus target price of $579.75, suggesting a potential upside of 29.70%. Given Chemed's stronger consensus rating and higher possible upside, analysts plainly believe Chemed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	3 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Chemed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Medpace beats Chemed on 9 of the 16 factors compared between the two stocks.